StemCell Therapy

This report also researches and evaluates the impact of Covid-19 outbreak on the Animal Stem Cell Therapy industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Animal Stem Cell Therapy and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.).

Latest Market Research Report onAnimal Stem Cell Therapy Market size | Industry Segment by Applications (Veterinary Hospitals and Research Organizations), by Type (Dogs, Horses and Others), Regional Outlook, Market Demand, Latest Trends, Animal Stem Cell Therapy Industry Share & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2025.Analyzes current market size and upcoming 5 years growth of this industry.

The report also assesses driving forces of Animal Stem Cell Therapy market and changing dynamics which have been examined as growth-boosting factor. Also, the Animal Stem Cell Therapy study sheds light on limitations and restraints that could probably become obstruction while the Animal Stem Cell Therapy industry is proceeding to achieve substantial revenue. The report also aids readers to gain in-depth knowledge of a Animal Stem Cell Therapy market environment that comprises terms such as entry barriers, and trading policies as well as regulatory, political, financial and social concerns that may also hamper Animal Stem Cell Therapy market growth momentum.

Request Sample Copy of this Report @ https://www.zzreport.com/request-sample/1189

It also facilitates clients with the acumen to gain competitive advantages in the Animal Stem Cell Therapy market and the strengths and weaknesses of their strong opponents. The Animal Stem Cell Therapy report emphasizes their strategic movements including brand expansions, public relations activities and product releases. The report highlights ideas, objectives, core business values, and niche markets of leading contributors operating in the worldwide Animal Stem Cell Therapy industry.

Manufacturer / Potential Investors, Traders, Distributors, Wholesalers, Retailers, Importers and Exporters, Association and government bodies are the main audience for Animal Stem Cell Therapy market involved in this report.

Report Scope:

Animal Stem Cell Therapy market competition by top Manufacturers:

Animal Stem Cell Therapy Market Outlook by Applications:

Animal Stem Cell Therapy Market Statistics by Types:

The study includes the profiles of key players in the Animal Stem Cell Therapy market with a significant global and/or regional presence. The study on the global Animal Stem Cell Therapy market includes qualitative factors such as drivers, restraints, and opportunities. The study covers the qualitative and quantitative analysis of the market segmented based on type, technology, and vertical. Moreover, the study provides similar information for the key geographies.

With the clear insight this report also helps in understanding Animal Stem Cell Therapy market dynamics, structure by analyzing the Animal Stem Cell Therapy market segments, and project the Animal Stem Cell Therapy market size. Actual market sizes and forecasts have been provided for all the above-mentioned segments.

The foremost points are labelled in detail which are covered in this Animal Stem Cell Therapy Market Report:

The Animal Stem Cell Therapy Analysis report offers an entire substantial study of the Animal Stem Cell Therapy market, key tactics followed by leading Animal Stem Cell Therapy industry Players and impending segments. The previous and current Animal Stem Cell Therapy industry forecast analysis in terms of volume and value along with research conclusions is a decisive part of Animal Stem Cell Therapy market analysis report.

Request Customization on This Report @ https://www.zzreport.com/request-for-customization/1189

More:
Animal Stem Cell Therapy Market Research, Recent Trends and Growth Forecast 2025 - ZZReport

- Company's goal to initiate clinical trial in patients in 2020

- Innovative therapy candidate uses next generation mesenchymal stem cells (MSCs) derived from a master cell bank of induced pluripotent stem cells (iPSCs)

CRANFORD, N.J., April 27, 2020 /PRNewswire/ --Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it submitted a pre-IND meeting request and supporting briefing documents to the Center for Biologics Evaluation and Research ("CBER") of the FDA under the Coronavirus Treatment Acceleration Program (CTAP) on April 24. The Company has requested the Division's feedback to support the most expeditious pathway into the clinic to evaluate a novel cell therapy in patients suffering from COVID-19-related ARDS.

The cells, called NoveCite Cells or NC-MSCs, are made by Novellus, Inc. ("Novellus"), a Cambridge-based biotechnology company, using its patented mRNA-based cell-reprogramming process. NC-MSCs are mesenchymal stem cells derived from a single donor's fibroblasts that have been dedifferentiated into an induced pluripotent stem cell (iPSC) master cell bank, thereby avoiding the need to source additional donor cells. The iPSCs are then further differentiated into a mesenchymal stem cell (MSC) therapy. Citius and Novellus plan to develop NC-MSCs for the treatment of ARDS, and last month the companies signed an exclusive option agreement.

The Company plans a multi-center randomized placebo-controlled dose-finding study followed by an expansion phase to assess the safety, tolerability, and efficacy of NC-MSCs in patients with moderate to severe ARDS due to COVID-19. The proposed trial, a Phase 1b/2 clinical trial, is titled "A Randomized Placebo-Controlled Dose-Finding Study Followed by a Dose Level Expansion to Assess the Safety and Efficacy of NoveCite MSCs in Subjects with Acute Respiratory Distress Syndrome (ARDS) Due to SARS-CoV-2 Disease (COVID-19)," or "MARCO". The primary objectives of this study are to evaluate the safety and efficacy of NoveCite cells as a treatment for subjects with moderate-to-severe ARDS due to COVID-19 and to identify therapeutic doses.

"MSCs have an established track-record of clinical safety, and have shown promise in the treatment of inflammatory lung disease," said Matt Angel, PhD, co-founder and Chief Science Officer at Novellus, Inc. "Our research has shown that the NoveCite cells, being derived from mRNA-reprogrammed iPSCs, secrete higher levels of immunomodulatory proteins than donor-derived MSCs, and have unique manufacturing advantages."

"We believe we have the key elements in place from a clinical design and manufacturing point of view to evaluate this novel cell therapy approach to deal with the current pandemic," said Myron Holubiak, Chief Executive Officer of Citius. "ARDS is a very serious complication for many patients suffering from COVID-19, and is believed to account for about 80% of the deaths in ventilated patients. There is no proven or FDA-approved treatment for it, other than oxygen therapy, including use of mechanical ventilation, and fluid management. Literature from previous investigational studies with MSCs in the treatment of lung injuries support the idea that MSCs could prove effective in treating COVID-19-related ARDS. We look forward to our FDA discussions and are excited to be at the cusp of what could be a novel and effective therapy for ARDS."

About Acute Respiratory Distress Syndrome (ARDS)ARDS is a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs. ARDS is a rapidly progressive disease that occurs in critically ill patients most notably now in those diagnosed with COVID-19. ARDS affects approximately 200,000 patients per year in the U.S., exclusive of the current COVID-19 pandemic, and has a 30% to 50% mortality rate. ARDS is sometimes initially diagnosed as pneumonia or pulmonary edema (fluid in the lungs from heart disease). Symptoms of ARDS include shortness of breath, rapid breathing and heart rate, chest pain (particularly while inhaling), and bluish skin coloration. Among those who survive ARDS, a decreased quality of life is relatively common.

Story continues

About Coronavirus Treatment Acceleration Program (CTAP)In response to the pandemic, the FDA has created an emergency program called the Coronavirus Treatment Acceleration Program (CTAP) to accelerate the development of treatments for COVID-19. By redeploying staff, the FDA is responding to COVID-19-related requests and reviewing protocols within 24 hours of receipt. The FDA said CTAP "uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful." In practice, that means developers of potential treatments for COVID-19 will benefit from an unusually faster track at the FDA to shorten wait times at multiple steps of the process.

About Citius Pharmaceuticals, Inc.Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. For more information, please visit http://www.citiuspharma.com.

About Novellus, Inc.Novellus is a pre-clinical stage biotechnology company developing engineered cellular medicines using its non-immunogenic mRNA, nucleic-acid delivery, gene editing, and cell reprogramming technologies. Novellus is privately held and is headquartered in Cambridge, MA. For more information, please visit http://www.novellus-inc.com.

Safe HarborThis press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk of successfully negotiating a license agreement with Novellus within the option period; our need for substantial additional funds; the ability to access the FDA's CTAP program for the MARCO trial; the estimated markets for our product candidates, including those for ARDS, and the acceptance thereof by any market; risks associated with conducting trials for our product candidates, including those expected to be required for any treatment for ARDS and our Phase III trial for Mino-Lok; risks relating to the results of research and development activities; risks associated with developing our product candidates, including any licensed from Novellus, including that preclinical results may not be predictive of clinical results and our ability to file an IND for such candidates; uncertainties relating to preclinical and clinical testing; the early stage of products under development; risks related to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close, and integrate product candidates and companies successfully and on a timely basis; our ability to attract, integrate, and retain key personnel; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law.

Contact:Andrew ScottVice President, Corporate Development(O) 908-967-6677 x105 ascott@citiuspharma.com

View original content:http://www.prnewswire.com/news-releases/citius-announces-pre-ind-submission-to-fda-under-the-coronavirus-treatment-acceleration-program-for-a-novel-stem-cell-therapy-for-acute-respiratory-distress-syndrome-ards-in-covid-19-301047150.html

SOURCE Citius Pharmaceuticals, Inc.

Read this article:
Citius Announces Pre-IND Submission to FDA Under the Coronavirus Treatment Acceleration Program for a Novel Stem Cell Therapy for Acute Respiratory...

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc. (AgeX; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced that based on a strategic review of its operations, giving consideration to the status of its product development programs, human resources, capital needs and resources, and current conditions in the capital markets resulting from the COVID-19 pandemic, it is initiating staff layoffs, anticipated to affect 12 employees, primarily research and development personnel. The layoffs are expected to be completed on or around May 1, 2020. AgeX expects to pay approximately $105,000 in accrued payroll and unused paid time off and other benefits and expects to recognize approximately $194,800 in restructuring charges in connection with the reduction in staffing, consisting of contractual severance and other employee termination benefits, substantially all of which are expected to be settled in cash.

AgeX plans to continue to pursue its licensing and collaboration strategy for its two primary technology platforms, UniverCyte immunotolerance technology, and PureStem cell derivation and manufacturing technology. Since the launch of its licensing and collaboration strategy in January 2020, AgeX delivered a research collaboration in Japan focused on developing universally transplantable cells for therapeutic use based on UniverCyte, and entered into a neural stem cell therapy research collaboration for neurological disorders utilizing PureStem at a California state university. AgeXs budgetary and personnel adjustments will result in the deferral of in-house work on the development of AgeX therapy product candidates, including AGEX-VASC1 and AGEX-BAT1, and its induced tissue regeneration (iTR) technology, and may also lead to outsourcing of some of that work, until further funding can be obtained to rebuild a research and development staff for one or more of those programs. Development of AgeXs iTR technology may be done at AgeXs subsidiary Reverse Bioengineering, Inc. subject to successful financing of the subsidiary.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan, and is seeking opportunities to establish licensing and collaboration arrangements around its broad IP estate and proprietary technology platforms.

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the Risk Factors section of AgeXs most recent Annual Report on Form 10-K filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

The rest is here:
AgeX Therapeutics Announces Reduction in Projected Cash Expenditures - Business Wire

In 2018, the market size of Canine Stem Cell Therapy Market is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2018; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Canine Stem Cell Therapy market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Canine Stem Cell Therapy market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Canine Stem Cell Therapy market to assist our clients arrive at beneficial business decisions.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/15550

This study presents the Canine Stem Cell Therapy Market production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. Canine Stem Cell Therapy history breakdown data from 2014 to 2018, and forecast to 2025.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2018.

In global Canine Stem Cell Therapy market, the following companies are covered:

Company Profiles

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/15550

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Canine Stem Cell Therapy product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top manufacturers of Canine Stem Cell Therapy, with price, sales, revenue and global market share of Canine Stem Cell Therapy in 2017 and 2018.

Chapter 3, the Canine Stem Cell Therapy competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Canine Stem Cell Therapy breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2018.

Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2018.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/15550

Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2018.

Chapter 12, Canine Stem Cell Therapy market forecast, by regions, type and application, with sales and revenue, from 2018 to 2024.

Chapter 13, 14 and 15, to describe Canine Stem Cell Therapy sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Read the original here:
Global Canine Stem Cell Therapy Market's Growth Trajectory Disrupted by COVID-19 Pandemic; Growth to be Restored Post Crisis Science Market Reports -...

Allosource

Stem Cell Therapy Market Competitive Landscape

In the last chapter, the analysts have studied the competitive landscape present in the Stem Cell Therapy market. The chapter also includes comments and recommendations by market experts to help the readers make the right decisions for their businesses for the forecast period. The chapter on competitive landscape presents a list of achievements made by these companies so far, mergers and acquisitions, and product innovations.

Stem Cell Therapy Market Segmentation

The extensive report on the Stem Cell Therapy market includes an executive summary that gives a brief description of the overall market, its drivers, restraints, leading segments, and competitive landscape. Each part of the executive is separately explained in the research report through dedicated chapters. The chapters are complete with precise calculations through charts and graphs.

The publication also includes individual chapters on various segments present in the market and the relevant sub-segments. Analysts have provided historical revenues and estimated revenues for all of the segments. Sales of products and the evolution of end-users have also been studied in the research report. The chapter on geographical analysis assesses the regional markets. It takes a granular view of the changing socio-political conditions, weather changes, and annual budgets of nations to determine their impact on the overall market.

We Offer up to 30% Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=NYH&utm_medium=001

Report Objectives

Analyzing the size of the Stem Cell Therapy market on the basis of value and volume.

Accurately calculating the market shares, consumption, and other vital factors of different segments of the Stem Cell Therapy market.

Exploring the key dynamics of the Stem Cell Therapy market.

Highlighting important trends of the Stem Cell Therapy market in terms of production, revenue, and sales.

Deeply profiling top players of the Stem Cell Therapy market and showing how they compete in the industry.

Studying manufacturing processes and costs, product pricing, and various trends related to them.

Showing the performance of different regions and countries in the Stem Cell Therapy market.

Forecasting the market size and share of all segments, regions, and the global market.

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market, By Solution

6.1 Overview

7 Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Stem Cell Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get Complete Report @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=NYH&utm_medium=001

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Analysis

Our Trending Reports

Metabolomics Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Stem Cell Therapy Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more:
Stem Cell Therapy Market Growth Opportunities, Key Companies, Outlook, Drivers and Forecast to 2026 - New York Headlines USA

Aging is an inevitable process. We cannot escape or prevent getting older but what if theres a fascinating field of medicine that can manage the aging process and prolong our health and vitality and longevity as we age?

Aging is an inevitable process. We cannot escape or prevent getting older but what if theres a fascinating field of medicine that can manage the aging process and prolong our health and vitality and longevity as we age?

Keeping in mind that there may never be an approach to totally stop or reverse aging, there have been some surprising disclosures to how Regenerative Medicine can naturally heal our body without the use of any surgical procedure.

Rejuvenating Old Cells to Healthy ones

The paces, stresses, and complexities in life drive us to age prematurely thereby breaking down our cells. Cell breakdown may lead to several health conditions like cancer, heart disease, Alzheimers and others.

Driving our bodies to age quickly, cell-breakdown is host to many age-related diseases, causing more than 100,000 deaths per day.

Dr David C Karli is an Ivy-trained physician, specialized in treating athletic injuries by inducing regenerative medicine and stem cell therapy in treatments.

He accepts the fact that patients can increase an additional 30 years of life by using Regenerative Medicine. One such innovation uses stem cells, however, there are issues with these cells.

They may not replace the original, diseased cells rapidly enough, or they may start to replicate uncontrollably, bringing about malignant growth.

Yet, Regenerative Medicine definitely guarantees the complete curing of a wide range of diseases, and ideally, slowing down the aging process too.

Stem Cell Therapy Programs with Promising Results

With solid funding and rapid advancements, one stem cell therapy that promises great outcomes is transfusions. In this therapy, stem cells are extracted from the patient and grown in cell culture to increase the number of cells. Following this, those cells are injected back into the patients body.

Dr. Karlis keen interest in Transfusions led him to create biologic products that can cause an age-related decline in a persons strength, endurance, and various other physical abilities.

At his biotech firm, Greyledge Technologies, biologic products are prepared by processing materials (blood or bone marrow) and implanting them into the human body to replicate the diseased tissues.

With an FDA-registered laboratory environment, the outcomes are promising and are an anti-aging protocol.

Telomeres may be the next-gen solution for Anti Aging

Telomeres are essential parts of our DNA that are connected to the premature aging cells. Situated at the end caps of our DNA strands, the information within Telomeres is lost while DNA replicates to the extent that they stop replicating.

If DNA replicates without losing information, scientists believe that Telomeres can significantly help to slow down the aging process.

Similar is the case with Metformin, a pharmaceutical reagent that improves wound healing. Proven to counteract aging, Metformin is now being tested for its unique ability to mimic calorie restriction.

Anti-Aging Through Regeneration

Utilizing induced tissue regeneration, this technology is a new approach to anti-aging treatment. Combining telomerase therapy and induced tissue regeneration, anti-aging through regeneration includes the study of the impact on age-related diseases like diabetes, metabolic disorders, cardiovascular disease, and others.

This technique focuses on the cells that are generated in our body during youth. As we age, these cells are lost and lead to a metabolic imbalance.

Scientists and Researchers are trying to find a way in which these cells can be restored to reverse the signs of aging and create a balance.

Humans have the ability to regenerate damaged and diseased tissues. However, this only happens during the first few weeks of development. With the help of Artificial Intelligence, scientists are trying to unlock this potential ability in humans.

The Future of Anti-Aging

With several breakthroughs on the horizon, cure-all promises and best outcomes, these anti-aging protocols have a long way to go.

While the introduction of regenerative medicine and stem cell therapies to redefine orthopedic treatment sounds like a miracle, there are still unexplored paths that need to be taken.

With all the benefits regenerative medicine has to offer, there will always be an eye on the never-ending search for the fountain of youth.

CLICK HERE FOR BREVARD COUNTY NEWS

Read the rest here:
Dr. David C. Karli's Opinion on Regenerative Medicine and Age Prevention | - SpaceCoastDaily.com

Ventilator-dependent COVID-19 patients with moderate/severe acute respiratory distress syndrome (ARDS) who were treated with intravenous infusions of an allogeneic mesenchymal stem cell product candidate had a survival rate of 83%.

The allogeneic mesenchymal stem cell product candidate remestemcel-L from Mesoblast Limited (Melbourne, Australia) was administered within the first five days under emergency compassionate use at New York Citys Mt Sinai hospital during the period March-April 2020. Patients received a variety of experimental agents prior to remestemcel-L. All patients were treated under an emergency Investigational New Drug (IND) application or expanded access protocol at Mt Sinai hospital. 75% of the patents successfully came off ventilator support within a median of 10 days, in contrast to only 9% of ventilator-dependent COVID-19 patients being able to come off ventilators with standard of care treatment and only 12% survival in ventilator-dependent COVID-19 patients at two major referral hospital networks in New York during the same time period. These poor outcomes are consistent with earlier published data from China where mortality rates of over 80% were reported in patients with COVID-19 and moderate/severe ARDS.

The remarkable clinical outcomes in these critically ill patients continue to underscore the potential benefits of remestemcel-L as an anti-inflammatory agent in cytokine release syndromes associated with high mortality, including acute graft versus host disease and COVID-19 ARDS, said Mesoblast Chief Executive Dr. Silviu Itescu. We intend to rapidly complete the randomized, placebo-controlled Phase 2/3 trial in COVID-19 ARDS patients to rigorously confirm that remestemcel-L improves survival in these critically ill patients.

There is a significant need to improve the dismal survival outcomes in COVID-19 patients who progress to ARDS and require ventilators, said Mesoblast Chief Medical Officer Dr Fred Grossman. We have implemented robust statistical analyses in our Phase 2/3 trial as recommended by the US Food and Drug Administration (FDA) in order to maximize our ability to evaluate whether remestemcel-L provides a survival benefit in moderate/severe COVID-19 ARDS.

Related Links:Mesoblast Limited

View post:
Stem Cell Therapy Shows 83% Survival in COVID-19 Patients Dependent on Ventilator - HospiMedica

Allosource

Global Stem Cell Therapy Market: Competitive Landscape

This section of the report lists various major manufacturers in the market. The competitive analysis helps the reader understand the strategies and collaborations that players focus on in order to survive in the market. The reader can identify the players fingerprints by knowing the companys total sales, the companys total price, and its production by company over the 2020-2026 forecast period.

Global Stem Cell Therapy Market: Regional Analysis

The report provides a thorough assessment of the growth and other aspects of the Stem Cell Therapy market in key regions, including the United States, Canada, Italy, Russia, China, Japan, Germany, and the United Kingdom United Kingdom, South Korea, France, Taiwan, Southeast Asia, Mexico, India and Brazil, etc. The main regions covered by the report are North America, Europe, the Asia-Pacific region and Latin America.

The Stem Cell Therapy market report was prepared after various factors determining regional growth, such as the economic, environmental, technological, social and political status of the region concerned, were observed and examined. The analysts examined sales, production, and manufacturer data for each region. This section analyzes sales and volume by region for the forecast period from 2020 to 2026. These analyzes help the reader understand the potential value of investments in a particular country / region.

We Offer up to 30% Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=COD&utm_medium=003

Key Benefits for Stakeholders:

The report provides an in-depth analysis of the size of the Stem Cell Therapy world market, as well as recent trends and future estimates, in order to clarify the upcoming investment pockets.

The report provides data on key growth drivers, constraints and opportunities, as well as their impact assessment on the size of the Stem Cell Therapy market.

Porters 5 Strength Rating shows how effective buyers and suppliers are in the industry.

The quantitative analysis of the Stem Cell Therapy world industry from 2020 to 2026 is provided to determine the potential of the Stem Cell Therapy market.

This Stem Cell Therapy Market Report Answers To Your Following Questions:

Who are the main global players in this Stem Cell Therapy market? What is the profile of your company, its product information, its contact details?

What was the status of the global market? What was the capacity, the production value, the cost and the profit of the market?

What are the forecasts of the global industry taking into account the capacity, the production and the value of production? How high is the cost and profit estimate? What will be the market share, supply, and consumption? What about imports and export?

What is market chain analysis by upstream raw materials and downstream industry?

Get Complete Report @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=COD&utm_medium=003

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Analysis

View post:
Stem Cell Therapy Market Growth Opportunities, Challenges, Key Companies, Drivers and Forecast to 2026 Cole Reports - Cole of Duty

Global Stem Cell Therapy market report presents an overview of the market on the basis of key parameters such as market size, revenue, sales analysis and key drivers. The market size of global Stem Cell Therapy market is anticipated to grow at large scale over the forecast period (2020-2025). The main purpose of the study report is to give users an extensive viewpoint of the market. So that users can apply strategic processes to benchmark themselves against rest of the world. Key drivers as well as challenges of the market are discussed in the report. Also reports provides an in depth analysis of the Stem Cell Therapy market with current and future trends.

Get Sample Copy of this Report:https://www.adroitmarketresearch.com/contacts/request-sample/691

In addition, study report offers an array of opportunities for the players participating in the industry. This ultimately leads into the growth of the global Stem Cell Therapy market. Furthermore, report offers a comprehensive study on market size, revenue, sales, growth factors and risks involved in the growth of the market during the forecast period. The factors which are influencing the growth the market are mentioned in the report as well as the challenges which can hamper the growth of the market over the forecast period.

In addition, report presents quantitative as well as qualitative narration of global Stem Cell Therapy market. The research report is beneficial for educators, researchers, strategy managers, academic institutions and analysts. Thus report helps all types of users to identify the strategic initiatives so that they can understand how to expand the global Stem Cell Therapy market business across the globe for the product development. Moreover, research report provides in depth analysis of all the segments which can impact on the market growth.

Browse the complete report @https://www.adroitmarketresearch.com/industry-reports/stem-cell-therapy-market

Global Stem Cell Therapy market is segmented based by type, application and region.

Based on cell source, the market has been segmented into,

Adipose Tissue-Derived Mesenchymal SCsBone Marrow-Derived Mesenchymal SCsEmbryonic SCsOther Sources

Based on therapeutic application, the market has been segmented into,

Musculoskeletal DisordersWounds & InjuriesCardiovascular DiseasesGastrointestinal DiseasesImmune System DiseasesOther Applications

The company profile section also focusses on companies planning expansions along with mergers & acquisitions, new initiatives, R&D updates and financial updates. But, one of the most important aspects focused in this study is the regional analysis. Region segmentation of markets helps in detailed analysis of the market in terms of business opportunities, revenue generation potential and future predictions of the market. For Stem Cell Therapy report, the important regions highlighted are North America, South America, Asia, Europe and Middle East. The companies focused on in this report are pioneers in the Stem Cell Therapy market. Right from history to future plans the report give a detailed roadmap of the industry that the readers can rely on. The uplifting of any region in the global market is dependent upon the market players working in that region.

In the final section of the report on Stem Cell Therapy Market, the dashboard view of the companies is provided, to compare the current industrial scenario and their contribution in total Stem Cell Therapy Market. Moreover, it is primarily designed to provide clients with an objective and detailed comparative assessment of key providers specific to a market segment. Report audiences can gain segment-specific manufacturer insights to identify and evaluate key competitors based on the in-depth assessment of their capabilities and success in the Stem Cell Therapy Marketplace.

For Any Query on the Stem Cell Therapy Market:https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/691

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more from the original source:
Global Stem Cell Therapy Market 2020: Growth, Demand, Service, Types, Applications, Key Players and Industry Forecast till 2025 - Latest Herald

COVID-19 Analysis on the Global Rheumatoid Arthritis Stem Cell Therapy Market

A recent market research report on the Rheumatoid Arthritis Stem Cell Therapy market published by Fact.MR is an in-depth assessment of the current landscape of the market. Further, the report elaborates on the impact of the COVID-19 on the Rheumatoid Arthritis Stem Cell Therapy market and provides a thorough understanding of the growth potential of each market segment over the forecast period (2020-2030).

According to the analyst at Fact.MR, the Rheumatoid Arthritis Stem Cell Therapy market is evenly slated to register a CAGR growth of ~XX% during the assessment period and attain a value of ~US$ XX by the end of 2030. The report analyzes the micro and macro-economic factors that are projected to impact the growth of the Rheumatoid Arthritis Stem Cell Therapy market in the upcoming years. Further, a detailed analysis of the business continuity strategies of leading market participants is enclosed in the presented report.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=1001

Key Insights Enclosed in the Report

Segmentation of the Rheumatoid Arthritis Stem Cell Therapy Market

The presented report dissects the Rheumatoid Arthritis Stem Cell Therapy market into different segments and ponders over the current and future prospects of each segment. The report depicts the year-on-year growth of each segment and touches upon the different factors that are likely to influence the growth of each market segment. Further, projections are made taking into account the impact of the COVID-19 pandemic on the each market segment.

The various segments of the Rheumatoid Arthritis Stem Cell Therapy market analyzed in the report include:

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=1001

Important doubts related to the Rheumatoid Arthritis Stem Cell Therapy market clarified in the report:

Why Choose Fact.MR

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=1001

Original post:
COVID-19 Outbreak Bestows Lucrative Opportunities to Rheumatoid Arthritis Stem Cell Therapy Market; Demand to Remain High Post Pandemic - Latest...

NEW YORK, April 15, 2020 /PRNewswire/ -- The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market. However, high cost related of the stem cell therapy limits the growth of the market.Stem cell research has been widely investigated globally for various medical applications, especially for the treatment of humans.This raises the importance of creating public awareness about stem cell research and its clinical potential.

The main role of stem cells is in the replacement of dying cells and reconstruction of damaged tissues. Based on the extensive stem cell research, many scientists have claimed that these cells could probably be used in the treatment of various diseases, including cancer and cardiovascular disease.There is a large number of potential treatment procedures that are undergoing clinical trials, and a notably few stem cell therapies have won FDA (i.e., US Food and Drug Administration) approval for clinical usage. For instance, in 2019, the FDA approved Fedratinib for the first-line treatment for myelofibrosis. Moreover, stem cell therapies are widely used in bone marrow transplantation, and these therapies have benefited thousands of people suffering from leukemia. Hematopoietic stem cells are used for treating more than 80 medical diseases, including immune system disorders, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers, such as leukemia and lymphoma; this is also likely to boost the demand for this treatment procedure during the forecast period. Researchers are further investigating the use of stem cell therapies in the treatment of autoimmune disorders.

The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user.Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others.

The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period.Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous.

The allogeneic segment held a larger share of the market in 2019; however, the market for the autologous segment is expected to grow at a higher CAGR during the forecast period.Based on application type, the stem cell therapy market has been segmented into musculoskeletal, dermatology, cardiology, drug discovery and development, and other applications.

The musculoskeletal segment held the largest share of the stem cell therapy market in 2019, whereas the drug discovery and development segment is expected to report the highest CAGR during 20202027. Based on end user, the market has been segmented into academic and research institutes, and hospitals and specialty clinics. The academic & research institutes held the largest share of the market in 2019, and it is also expected to report the highest CAGR during the forecast period.Several essential secondary sources referred to for preparing this report are the FDA, World Health Organization (WHO), Organisation for Economic Co-operation and Development, National Institutes of Health, Spanish Agency for Medicines (AEMPS), Japanese Society for Regenerative Medicine, and Indian Council of Medical Research, among others.

Read the full report: https://www.reportlinker.com/p05882135/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/stem-cell-therapy-market-to-2027---global-analysis-and-forecasts-by-type-treatment-application-end-user-and-geography-301041155.html

SOURCE Reportlinker

Follow this link:
Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography - Yahoo Finance

Analysis Report on Canine Stem Cell Therapy Market

A report on global Canine Stem Cell Therapy market has hit stands. This study is based on different aspects like segments, growth rate, revenue, leading players, regions, and forecast. The overall market is getting bigger at an increased pace due to the invention of the new dynamism, which is making rapid progress.

The given report is an excellent research study specially compiled to provide latest insights into critical aspects of the Global Canine Stem Cell Therapy Market.

Request Sample Report @https://www.mrrse.com/sample/16152?source=atm

Some key points of Canine Stem Cell Therapy Market research report:

Strategic Developments: The custom analysis gives the key strategic developments of the market, comprising R&D, new product launch, growth rate, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Market Features: The report comprises market features, capacity, capacity utilization rate, revenue, price, gross, production, production rate, consumption, import, export, supply, demand, cost, market share, CAGR, and gross margin. In addition, the report offers a comprehensive study of the market dynamics and their latest trends, along with market segments and sub-segments.

Analytical Tools: The Global Canine Stem Cell Therapy Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, feasibility study, and many other market research tools have been used to analyze the growth of the key players operating in the market.

COVID-19 Impact on Canine Stem Cell Therapy Market

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Canine Stem Cell Therapy market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Canine Stem Cell Therapy market is analyzed and depicted in the report.

The global Canine Stem Cell Therapy market segment by manufacturers include

Market Taxonomy

The global canine stem cell therapy market has been segmented into:

Product Type:

Application:

End User:

Region:

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/16152?source=atm

Important queries addressed in the report:

Moreover, the report highlighted revenue, sales, manufacturing cost, and product and the States that are most competitive in the lucrative market share idea. There is a discussion on the background and financial trouble in the global Canine Stem Cell Therapy economic market. This included the CAGR value during the outlook period leading to 2025.

Buy This Report @ https://www.mrrse.com/checkout/16152?source=atm

Benefits of Purchasing Canine Stem Cell Therapy Market Report:

Inimitable Expertise: Analysts will provide deep insights into the reports.

Analyst Support: Get your query resolved from our team before and after purchasing the report.

Customers Satisfaction: Our team will assist with all your research needs and customize the report.

Assured Quality: We focus on the quality and accuracy of the report.

Conclusively, this report will provide you a clear view of each and every fact of the market without a need to refer to any other research report or a data source. Our report will provide you with all the facts about the past, present, and future of the concerned Market.

Read this article:
Potential impact of coronavirus outbreak on Canine Stem Cell Therapy Market Size, Top Manufacturers, Product Types, Applications and Specification,...

Allosource

Stem Cell Therapy Market: Competitive Landscape

The last chapter of the Stem Cell Therapy market research report focuses exclusively on the competitive landscape. It examines the main market players. In addition to a brief overview of the business, analysts provide information on their assessment and development. The list of important products in preparation is also mentioned. The competitive landscape is analyzed by understanding the companies strategies and the initiatives they have taken in recent years to overcome intense competition.

Stem Cell Therapy Market: Drivers and Restraints

The report explains the drivers of the future of the Stem Cell Therapy market. It assesses the different forces which should have a positive impact on the whole market. Analysts have looked at investments in research and development for products and technologies, which should give players a significant boost. In addition, the researchers undertook an analysis of the evolution of consumer behavior which should have an impact on the cycles of supply and demand in the Stem Cell Therapy market. In this research report, changes in per capita income, improvement in the economic situation and emerging trends were examined.

The research report also explains the potential restrictions on the Stem Cell Therapy market. The aspects assessed are likely to hamper market growth in the near future. In addition to this assessment, it offers a list of opportunities that could prove lucrative for the entire market. Analysts offer solutions to turn threats and restrictions into successful opportunities in the years to come.

Stem Cell Therapy Market: Regional Segmentation

In the following chapters, analysts have examined the regional segments of the Stem Cell Therapy market. This gives readers a deeper insight into the global market and allows for a closer look at the elements that could determine its evolution. Countless regional aspects, such as the effects of culture, environment and government policies, which affect regional markets are highlighted.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=COD&utm_medium=007

What will the report contain?

Market Dynamics: The report contains important information on influencing factors, market drivers, challenges, opportunities and market trends as part of the market dynamics.

Global Market Forecast: Readers receive production and sales forecasts for the Stem Cell Therapy market, production and consumption forecasts for regional markets, production, sales and price forecasts for the Stem Cell Therapy market by type and consumption forecasts for the Stem Cell Therapy market per application.

Regional Market Analysis: It can be divided into two different sections: one for the analysis of regional production and one for the analysis of regional consumption. Here, analysts share gross margin, prices, sales, production, CAGR, and other factors that indicate the growth of all regional markets examined in the report.

Market Competition: In this section, the report provides information on the situation and trends of competition, including mergers and acquisitions and expansion, the market shares of the three or five main players and the concentration of the market. Readers could also get the production, revenue, and average price shares of manufacturers.

Key Players: The report provides company profiles for a decent number of leading players in the Stem Cell Therapy market. It shows your current and future market growth taking into account price, gross margin, income, production, service areas, production locations and other factors.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=COD&utm_medium=007

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Get Our Trending Report

Rich Mineral Paper Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Tags: Stem Cell Therapy Market Size, Stem Cell Therapy Market Trends, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Analysis

More:
Stem Cell Therapy Market 2020 Break Down by Top Companies, Applications, Challenges, Opportunities and Forecast 2026 Cole Reports - Cole of Duty

Denver Regenerative Medicine | Stem Cell Therapy, HRT, Testosterone Clinic, which is based in Denver, Colorado, has announced that they continue to evaluate patients but with the necessary precautions during the Covid closures. They realized that there could be people with back pain who cant wait for the quarantine to be over. For those who are looking for pain relief during this time, they can still schedule an appointment for back pain, and the clinic can still offer procedures as they are necessary medical care.

Dr. Joel Cherdack of Denver Regenerative Medicine says, If you feel that your back pain cant wait until the quarantine is over, dont hesitate to contact us. Well be taking all of the necessary precautions to avoid the spread of the virus but well be ready to serve your needs.

He continues, There are many advantages to stem cell therapy at our Denver Regenerative medicine clinic over surgery including faster recovery, less pain, lower cost, decreased or eliminated need to immobilize with a sling or cast and other benefits as well. Before any procedure takes place, we will meet with you for an initial consultation to evaluate your injuries and determine the best stem cell injection options for you.

Stem cells are extracted from the body of the patient and may be used to treat pain through the regeneration of damaged tissue. These cells are self-renewing and can grow into any kind of cell required by the body. Because stem cells from the patient are used to establish a customized treatment plan, there is less risk of the body rejecting the cells and can enhance the bodys own natural rejuvenating abilities.

The stem cell therapy procedure has three basic steps. First, the stem cells are extracted from bone marrow, body fat, or other tissue. Second, the stem cells are conditioned to maximize their healing capability. And third, the stem cells are injected into the area where they can have their maximum effect. Denver Regenerative Medicine utilizes stem cell therapy for the treatment of the deterioration of the joints of the elbows, knees, hips, and shoulders and to enhance the healing of soft tissues. Those who would like to know more about stem cell therapy and the clinic may want to follow the Denver Regenerative Medicine Facebook page.

Meanwhile, hormone replacement therapy (HRT) is offered for hormone imbalance problems. For men, HRT may be able to combat a number of symptoms, such as reduced interest in sex, erectile dysfunction, lower muscle mass and increased body fat, fatigue, loss of body and facial hair, and depression and cognitive issues. For women, HRT may be able to deal with a number of issues, such as thinning hair; irregular menstrual cycles; painful or unusually heavy periods; weight gain; increased growth of hair on the face, chest, neck, or back; hot flashes; and vaginal dryness.

Also available is the REjuvenate Therapy (for Men & Women), which is a combination of stem cell therapy and hormone replacement therapy. The combination results in a synergy between the two treatments to fight the illnesses caused by hormone imbalance, which could be the result of toxins, stress, and other natural factors.

Denver Regenerative Medicine also offers the unique AcCELLerate Stem Cell regeneration system. It combines the patients own stem cells and platelet rich plasma (PRP) for a combination of activated stem cells and platelets. This combination allows all of the growth factors from the PRP to immediately activate the stem cells. Patients who received this combination of stem cells and activated platelets noticed results about 30 percent faster compared to those who only received stem cells. Furthermore, the improvement was sustained over a longer period for the patients who received the AcCELLerate Stem Cell therapy.

Those who are interested in stem cell therapy and the other therapies available at Denver Regenerative Medicine | Stem Cell Therapy, HRT, Testosterone Clinic may want to check out their website at https://denverregenerativemedicine.com/, or contact them on the telephone, or through email. They are open from 10:00 am to 6:00 pm on Mondays, and from 8:00 am to 6:00 pm, from Tuesday to Thursday.

###

For more information about Denver Regenerative Medicine | Stem Cell Therapy, HRT, Testosterone Clinic, contact the company here:

Denver Regenerative Medicine | Stem Cell Therapy, HRT, Testosterone ClinicDr. Joel Cherdack(720) 583-1648info@denverregenerativemedicine.comDenver Regenerative Medicine | Stem Cell Therapy, HRT, Testosterone Clinic2149 S Holly St #200Denver, CO 80222

Visit link:
Stem Cell Therapy Clinic Still Evaluating Patients But with Precautions During Covid Closures - Press Release - Digital Journal

WASHINGTON, April 2, 2020 /PRNewswire/ -- An article published in Experimental Biology and Medicine (Volume 245, Issue 6, March 2020) (https://journals.sagepub.com/doi/pdf/10.1177/1535370220910690) examines the safety of stem cell therapy for the treatment of colon cancer.The study, led by Dr. J. Liu in the State Key Laboratory of Bioreactor Engineering and Shanghai Key Laboratory of New Drug Design at the East China University of Science and Technology in Shanghai (China), reports that mesenchymal stem cells from a variety of sources promote the growth and metastasis of colon cancer cells in an animal model.

Mesenchymal stem (MSCs), a category of adult stem cells, are being evaluated as therapy for numerous cancers.MSCs are excellent carriers for tumor treatment because they migrate to tumor tissues, can be genetically modified to secrete anticancer molecules and do not elicit immune responses.Clinical trials have shown that MSCs carrying modified genes can be used to treat colon cancer as well as ulcerative colitis. However, some studies have demonstrated MSCs can differentiate into cancer-associated fibroblasts and promote tumor growth.Therefore, additional studies are needed to evaluate the safety of MSCs for targeted treatment of colon cancer.

In the current study, Dr. Liu and colleagues examined the effects of mesenchymal stem cells (MSCs) from three sources (bone marrow, adipose and placenta) on colon cancer cells.MSCs from all three sources promoted tumor growth and metastasis in vivo. In vitro studies demonstrated that MSCs promote colon cancer cell stemness and epithelial to mesenchymal transition, which would enhance tumor growth and metastasis respectively.Finally, the detrimental effects of MSCs could be reversed by blocking IL-8 signaling pathways. Dr. Ma, co-author on the study, said that "Mesenchymal stem cells have a dual role: promoting and/or suppressing cancer. Which effect is dominant depends on the type of tumor cell, the tissue source of the MSC and the interaction between the MSC and the cancer cell. This is the major issue in the clinical application research of MSCs, and additional preclinical experimental data will be needed to evaluate the safety of MSCs for colon cancer treatment."

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology & Medicine, said: "Lui and colleagues have performed elegant studies on the impact of mesenchymal stem cells (MSCs), from various sources, upon the proliferation, stemness and metastasis of colon cancer stem cells (CSCs) in vitro and in vivo. They further demonstrate that IL-8 stimulates the interaction between colon CSCs and MSCs, and activates the MAPK signaling pathway in colon CSCs.This provides a basis for the further study of MSCs as a biologic therapy for colon cancer."

Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences. The journal was first established in 1903. Experimental Biology and Medicine is the journal of the Society of Experimental Biology and Medicine. To learn about the benefits of society membership, visit http://www.sebm.org. For anyone interested in publishing in the journal, please visit http://ebm.sagepub.com.

Related Images

logo.png Logo

View original content to download multimedia:http://www.prnewswire.com/news-releases/stem-cell-therapy-for-colon-cancer-301033659.html

SOURCE Experimental Biology and Medicine

Read the rest here:
Stem Cell Therapy for Colon Cancer - Yahoo Finance

By: New York Times | Published: April 2, 2020 10:59:26 pm On Saturday, the FDA took the unusual step of approving those drugs to treat hospitalized patients with coronavirus on an emergency basis, even though no significant clinical trials have yet been done.

Written by Katie Thomas

An experimental stem cell therapy derived from human placentas will begin early testing in patients with the coronavirus, a New Jersey biotech company said Thursday.

The treatment, being developed by the company Celularity, has not yet been used on any patients with symptoms of COVID-19, but it has caught the attention of Rudy Giuliani, President Donald Trumps personal lawyer. Giuliani recently featured an interview with the company founder on his website and said on Twitter that the product has real potential, while also criticizing the Food and Drug Administration for not moving more quickly to approve potential remedies.

There is no proven treatment for the respiratory disease, but several experimental approaches, including old malaria drugs and HIV antivirals, are being tested in patients around the world.

READ | Video from Japan shows how COVID-19 is getting transmitted through a third route

Celularity has also enthusiastically publicized the news of its early-stage trial for its treatment, known as CYNK-001. In an email Wednesday to a reporter, its public relations firm described a development as the first FDA approval for COVID-19 cell therapy. The agencys decision, however, merely gives a green light for its product to be used in a clinical trial, not widely prescribed to patients.

In recent weeks, the established scientific process of evaluating a drugs safety and effectiveness has been upended by Trump, who has repeatedly promoted the potential of two long-used malaria drugs that have shown mainly anecdotal evidence of helping patients. On Saturday, the FDA took the unusual step of approving those drugs to treat hospitalized patients with coronavirus on an emergency basis, even though no significant clinical trials have yet been done.

The early trial by Celularity which will primarily evaluate safety, as well as an initial look at efficacy will test its therapy in up to 86 patients with symptoms. They will receive infusions of the cell therapy in the hopes it will prevent them from developing the more severe form of the disease, Dr. Robert Hariri, Celularitys founder and chief executive, said in an interview Wednesday.

The objective here is preventative, Hariri said. If the timing of giving this can prevent those patients who have early disease from progressing to the more serious, life-threatening form, it could be a very, very useful tool.

The therapy involves using stem cells from the placenta known as natural killer cells that help protect a developing fetus or newborn from viruses that have infected the mother. Celularity has been testing these cells in cancer patients.

Hariri said the trial, which would not include a placebo control group, will take place at academic medical centers around the country. He said the company expected to see initial results about 30-60 days after the first patients receive their dose. If this study is successful, Hariri said, the company would move to a placebo-controlled study that would evaluate the drugs efficacy against the disease.

At least one outside expert said the approach could present safety risks. Paul Knoepfler, a stem cell researcher at the University of California, Davis, said that patients with coronavirus can develop severe reactions where their immune systems go too far in attacking cells in their lungs, causing damaging inflammation. Other cell therapies tested in China are designed to dampen the immune response. He said one risk with the natural killer cells is they could go in the other direction, exacerbating respiratory problems by massive killing of the patients respiratory cells.

Despite the scant evidence, Giuliani has become an early booster, interviewing Hariri on a podcast published on his website Saturday and praising the treatment on Twitter, saying, this therapy has real potential. In a tweet Saturday, he added, Lets hope FDA can recognize that their cumbersome process designed to keep us safer, if it is not altered dramatically in times of great need, can result in unimaginable loss of human life.

Around the same time, Twitter deleted a post by Giuliani that it said violated its rules. The tweet, from March 27, made unfounded claims about the malaria drug hydroxychloroquine, one of the treatments that Trump has supported.

Hariri said that he has known Giuliani for years and that the appearance on his podcast was a friendly chat between people who know each other and who share a common interest in this particular response to this disease.

He said that he has no business relationship with Giuliani, and that Giuliani is not representing him in any way, either paid or unpaid.

I dont have anything to do with what the mayor tweets or whatnot, and I dont agree or disagree with anything, he said.

Hariri said the company would follow the established process for testing whether a drug works.

We have waited for the FDA to complete their review, which they did in a heroic and quick fashion, he said.

On Wednesday evening the same day the FDA approved his trial Hariri praised the appearance by the agencys commissioner, Dr. Stephen Hahn, on the conservative Fox News talk show The Ingraham Angle.

We are fortunate to have Dr. Hahn at the helm, he tweeted.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Coronavirus Outbreak News, download Indian Express App.

Read the original post:
Unproven Stem Cell Therapy Gets OK for Testing in Coronavirus Patients - The Indian Express

Dr. Bart Rademaker is announcing that he will host online classes on stem cell therapy and its impact on the coronavirus.

TAMPA, Fla., April 2, 2020 /PRNewswire-PRWeb/ -- Dr. Bart Rademaker, the long-time plastic surgeon who has branched out into stem cell therapy, is offering online classes to patients and doctors who are interested in learning more about regenerative medicine and the potential benefits on health in particular during this time with the coronavirus or COVID-19. Rademaker, has offered the therapy in his office for years and has been contacted by physicians and patients who wish to find out more information on the benefits it could have for those combating the virus as clinical trials are proceeding in many parts of the world.. The classes will be available beginning in April 2020 and include podcasts, blogs and other forms of information that are available online.

"The coronavirus has turned the world upside down and people are trying to gather any information they can. I've heard medical experts tell people to drink warm tea or water every 20 minutes. I've heard patients say they read that you can kill the virus with stem cell therapy. There is too much information going out there right now and I want to help patients and medical professionals get the facts on it. Based on my experience and my communication with experts in the field of regenerative medicine, I feel that I can offer some assistance." Dr. Bart Rademaker

One of the main things the doctor wishes to stress to people who are unsure how to minimize exposure is that they need to follow the guidelines put in place by their government and information provided on personal hygiene and safety. This includes washing hands thoroughly with water and soap rather than rely on hand soap. Trying to avoid contact with your eyes and mouth unless you've recently washed your hands. Taking vitamins to strengthen your immune system. Staying away from people and avoiding areas like grocery stores as long as possible are other good recommendations provided that people should follow.

"People are not sure what to do because the information comes at them so quickly. Even doctors are not sure when their patient asks them if stem cell therapy is a safe option to prevent or treat the coronavirus. When I have doctors calling me just because they saw that I offer regenerative medicine information online, I knew it was time to start getting aggressive with these classes and offer my assistance to everyone."

For more information you can call our team at: 727-748-7389

About Dr. Bart Rademaker

Dr. Bart Rademaker is based in Tampa, Florida and has over 20 years of experience as a well-respected medical professional. He has affiliations with several hospitals including Morton Plant and Mease Countryside. His degree is from Erasmus University Rotterdam Faculty of Medicine and added regenerative medicine to his practice four years ago.

SOURCE Dr. Bart Rademaker

See the rest here:
Dr. Bart Rademaker Offers Free Classes On Stem Cell Therapy And The Coronavirus - Yahoo Finance

SOUTH SAN FRANCISCO, Calif., April 02, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation(FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Fluidigm CyTOF technology was used in a clinical study producing preliminary evidence that mesenchymal stem cell (MSC) therapy improves outcomes in patients with COVID-19 pneumonia, providing key information about potential mechanisms of action of the treatment strategy.

Results of the study, conducted by researchers in China, have been published in Aging and Disease.1

We used a 36-marker CyTOF panel to generate a broad immune profile of each patients peripheral blood before and after transplantation, said Wenjing Wang, PhD, Associate Professor at Beijing Hepatology Research Institute, Youan Hospital. Mass cytometry allowed us to look at all immune populations of interest in a single tube of peripheral blood mononuclear cells, enabling us to use less sample and to simplify our workflow and analysis.

The study, which evaluated clinical outcomes as well as changes in inflammatory and immune function for 14 days in seven patients with COVID-19 pneumonia, indicated that intravenous transplantation of MSCs was a safe and effective treatment for patients with COVID-19 pneumonia, including for those in severe condition.

Pulmonary function and symptoms of these seven patients were significantly improved within two days of MSC transplantation. Three of the patients, including one classified as severe, recovered and were discharged 10 days after treatment.

CyTOF analysis found that MSC treatment of severe cases led to disappearance in three to six days of overactivated cytokine-secreting immune cells and increases in regulatory T and dendritic cells. Importantly, there was a dramatic increase in a population of CD14+CD11c+CD11bmidregulatory dendritic cells, which may have helped to tamp down the cytokine storm associated with COVID-19 respiratory disease. Separate analysis of patient serum found significant reduction in levels of TNF-, a potent inflammatory cytokine, while IL-10, an anti-inflammatory cytokine, increased in the MSC treatment group compared to the placebo control group.

This level of new and valuable treatment research based on broad-based immune profiling is an important front in the COVID-19 fight, said Chris Linthwaite, President and CEO of Fluidigm. Fluidigm is actively engaged with many researchers in government and medical institutions who are addressing the COVID-19 pandemic from the perspectives of both immune profiling and virus detection and testing, and this study underscores the critical role that our technologies are playing in the global response to the outbreak.

In addition to our instruments, our assays and analysis software are increasingly the focus of customers in the global research community exploring immune profiling of COVID-19 infected populations. Our Maxpar Direct Immune Profiling Assay and Maxpar Pathsetter analysis software are a solution for labs seeking an easily deployed, fixed panel that can incorporate novel exploratory markers as well as standard markers, Linthwaite said.

We are inspired by this opportunity to provide meaningful tools in efforts to develop innovative solutions to this rapidly evolving pandemic.

About FluidigmFluidigm(FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visitfluidigm.com.

Fluidigm, theFluidigmlogo, CyTOF, Direct, Immune Profiling Assay, Maxpar, and Pathsetter are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.

Story continues

Forward-Looking Statements for FluidigmThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the implementation of Fluidigm microfluidics technology and products by third parties and the anticipated benefits of, and applications and demand for, such products. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to the potential adverse effects of the coronavirus pandemic on our business and operating results during 2020; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to company research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affectingFluidigmbusiness and operating results is contained in Fluidigms Annual Report on Form 10-K for the year endedDecember 31, 2019, and in its other filings with theSecurities and Exchange Commission. These forward-looking statements speak only as of the date hereof.Fluidigmdisclaims any obligation to update these forward-looking statements except as may be required by law.

1 Leng, Z., Zhu, R., Hou, W. et al. Transplantation of ACE2 mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging and Disease 11 (2020): 216228.

Contacts:

Media:Mark SpearmanSenior Director, Corporate Communications650 243 6621mark.spearman@fluidigm.com

Investors:Agnes LeeVice President, Investor Relations650 416 7423agnes.lee@fluidigm.com

Read more here:
Fluidigm CyTOF Technology Used to Evaluate Stem Cell Therapy as a Potential Treatment for COVID-19 Pneumonia - Yahoo Finance

Nerve Repair and Regeneration market worldwide is projected to grow by US$7. 1 Billion, driven by a compounded growth of 12. 1%. Neurostimulation & Neuromodulation Devices, one of the segments analyzed and sized in this study, displays the potential to grow at over 12.

New York, April 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nerve Repair and Regeneration Industry" - https://www.reportlinker.com/p05799212/?utm_source=GNW 3%. The shifting dynamics supporting this growth makes it critical for businesses in this space to keep abreast of the changing pulse of the market. Poised to reach over US$11.8 Billion by the year 2025, Neurostimulation & Neuromodulation Devices will bring in healthy gains adding significant momentum to global growth.

- Representing the developed world, the United States will maintain a 11% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$339.2 Million to the regions size and clout in the next 5 to 6 years. Over US$405.8 Million worth of projected demand in the region will come from Rest of Europe markets. In Japan, Neurostimulation & Neuromodulation Devices will reach a market size of US$527.3 Million by the close of the analysis period. As the worlds second largest economy and the new game changer in global markets, China exhibits the potential to grow at 16.1% over the next couple of years and add approximately US$1.4 Billion in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio. Several macroeconomic factors and internal market forces will shape growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.

- Competitors identified in this market include, among others,

Read the full report: https://www.reportlinker.com/p05799212/?utm_source=GNW

NERVE REPAIR AND REGENERATION MCP13MARKET ANALYSIS, TRENDS, AND FORECASTS, FEBRUARY 2CONTENTS

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW Nerve Repair and Regeneration Market Set for a Rapid Growth Neurostimulation and Neuromodulation Devices: Largest Product Segment Biomaterials to Exhibit Rapid Growth Nerve Repair and Regeneration Market by Application US and Europe Dominate the Market, Asia-Pacific to Register the Fastest Growth

2. FOCUS ON SELECT PLAYERS Abbott Laboratories, Inc. (USA) AxoGen, Inc. (USA) Boston Scientific Corporation (USA) Integra LifeSciences Corporation (USA) LivaNova, PLC (UK) Medtronic plc (USA) NeuroPace, Inc. (USA) Nevro Corporation.(USA) Orthomed S.A.S. (France) Polyganics B.V. (The Netherlands) Stryker Corporation (U.S.) Synapse Biomedical Inc. (U.S.) Synovis Micro Companies Alliance, Inc. (USA)

3. MARKET TRENDS & DRIVERS High Incidence of Brain Disorders and Nerve Injuries: Primary Market Driver EXHIBIT 1: Annual Incidence of Adult-Onset Neurologic Disorders in the US EXHIBIT 2: Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy EXHIBIT 3: Global Alzheimer's Prevalence by Age Group EXHIBIT 4: Diagnosed Prevalence Cases of Parkinsons Disease Across Select Countries Classification of Nerve Injuries Recent Developments in Spinal Cord Injury Treatment Rising Geriatric Population and Subsequent Growth in Prevalence Of Neurological Disorders EXHIBIT 5: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2and 2050 Intensified Research Activity Across Various Neural Disciplines Induces Additional Optimism Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration New Biomaterials Pave the Way for Innovative Neurodegeneration Therapies Role of Nerve Conduits in the Treatment of Peripheral Nerve Injury Innovative Nerve Conduits from Stryker Technological Advancements and Product Innovations - A Key Growth Driver Neurostimulation Allows Paralyzed People to Regain Leg Movement Neurostimulator to Treat Neurological Conditions Micro-Implantable Solution for Neurostimulation Parasym Device for Neurostimulation Boston Scientifics Spinal Cord Stimulation Improves Quality of Life Intellis Platform Presents Smallest Implantable Neurostimulator Innovation in Deep Brain Stimulation for Parkinsons Disease Innovations in Spinal Cord Stimulation for Pain Smart Neuromodulation: The Combination of AI and Neuromodulation Technologies New Dynamic Lead Interface Design for Neurostimulator Devices Wireless SCS Neuromodulation Therapy: An Alternative to Traditional SCS System Select Recent Approvals of Neuro-stimulation and Neuromodulation Devices Select Launches in Spinal Cord Stimulation (SCS) Market Select Launches in Deep Brain Stimulation (DBS) Market Select Neurostimulation Devices in Clinical Trials Select Neuromodulation Devices in Clinical Trials

4. GLOBAL MARKET PERSPECTIVE Table 1: Nerve Repair and Regeneration Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 2: Nerve Repair and Regeneration Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017 Table 3: Nerve Repair and Regeneration Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 Table 4: Neurostimulation & Neuromodulation Devices (Product) World Market by Region/Country in US$ Thousand: 2018 to 2025 Table 5: Neurostimulation & Neuromodulation Devices (Product) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 Table 6: Neurostimulation & Neuromodulation Devices (Product) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 Table 7: Biomaterials (Product) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025 Table 8: Biomaterials (Product) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017 Table 9: Biomaterials (Product) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 Table 10: Neurostimulation & Neuromodulation Surgeries (Application) Global Market Estimates & Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 11: Neurostimulation & Neuromodulation Surgeries (Application) Retrospective Demand Analysis in US$ Thousand by Region/Country: 2009-2017 Table 12: Neurostimulation & Neuromodulation Surgeries (Application) Market Share Breakdown by Region/Country: 2009 VS 2019 VS 2025 Table 13: Neurorrhaphy (Application) Demand Potential Worldwide in US$ Thousand by Region/Country: 2018-2025 Table 14: Neurorrhaphy (Application) Historic Sales Analysis in US$ Thousand by Region/Country: 2009-2017 Table 15: Neurorrhaphy (Application) Share Breakdown Review by Region/Country: 2009 VS 2019 VS 2025 Table 16: Nerve Grafting (Application) Worldwide Latent Demand Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 17: Nerve Grafting (Application) Global Historic Analysis in US$ Thousand by Region/Country: 2009-2017 Table 18: Nerve Grafting (Application) Distribution of Global Sales by Region/Country: 2009 VS 2019 VS 2025 Table 19: Stem Cell Therapy (Application) Sales Estimates and Forecasts in US$ Thousand by Region/Country for the Years 2through 2025 Table 20: Stem Cell Therapy (Application) Analysis of Historic Sales in US$ Thousand by Region/Country for the Years 2009 to 2017 Table 21: Stem Cell Therapy (Application) Global Market Share Distribution by Region/Country for 2009, 2019, and 2025 Table 22: Hospitals & Clinics (End-Use) Global Opportunity Assessment in US$ Thousand by Region/Country: 2018-2025 Table 23: Hospitals & Clinics (End-Use) Historic Sales Analysis in US$ Thousand by Region/Country: 2009-2017 Table 24: Hospitals & Clinics (End-Use) Percentage Share Breakdown of Global Sales by Region/Country: 2009 VS 2019 VS 2025 Table 25: Ambulatory Surgery Centers (End-Use) Worldwide Sales in US$ Thousand by Region/Country: 2018-2025 Table 26: Ambulatory Surgery Centers (End-Use) Historic Demand Patterns in US$ Thousand by Region/Country: 2009-2017 Table 27: Ambulatory Surgery Centers (End-Use) Market Share Shift across Key Geographies: 2009 VS 2019 VS 2025

III. MARKET ANALYSIS GEOGRAPHIC MARKET ANALYSIS UNITED STATES Table 28: United States Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 29: Nerve Repair and Regeneration Market in the United States by Product: A Historic Review in US$ Thousand for 2009-2017 Table 30: United States Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 31: United States Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 32: Nerve Repair and Regeneration Historic Demand Patterns in the United States by Application in US$ Thousand for 2009-2017 Table 33: Nerve Repair and Regeneration Market Share Breakdown in the United States by Application: 2009 VS 2019 VS 2025 Table 34: United States Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 35: Nerve Repair and Regeneration Historic Demand Patterns in the United States by End-Use in US$ Thousand for 2009-2017 Table 36: Nerve Repair and Regeneration Market Share Breakdown in the United States by End-Use: 2009 VS 2019 VS 2025 CANADA Table 37: Canadian Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 38: Canadian Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 39: Nerve Repair and Regeneration Market in Canada: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 40: Canadian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 41: Nerve Repair and Regeneration Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 42: Canadian Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 43: Canadian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 44: Nerve Repair and Regeneration Market in Canada: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 45: Canadian Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 JAPAN Table 46: Japanese Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 47: Nerve Repair and Regeneration Market in Japan: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 48: Japanese Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 49: Japanese Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 50: Japanese Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 51: Nerve Repair and Regeneration Market Share Shift in Japan by Application: 2009 VS 2019 VS 2025 Table 52: Japanese Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 53: Japanese Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 54: Nerve Repair and Regeneration Market Share Shift in Japan by End-Use: 2009 VS 2019 VS 2025 CHINA Table 55: Chinese Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 56: Nerve Repair and Regeneration Historic Market Analysis in China in US$ Thousand by Product: 2009-2017 Table 57: Chinese Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 58: Chinese Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 59: Nerve Repair and Regeneration Market Review in China in US$ Thousand by Application: 2009-2017 Table 60: Chinese Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 61: Chinese Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 62: Nerve Repair and Regeneration Market Review in China in US$ Thousand by End-Use: 2009-2017 Table 63: Chinese Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 EUROPE Table 64: European Nerve Repair and Regeneration Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025 Table 65: Nerve Repair and Regeneration Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017 Table 66: European Nerve Repair and Regeneration Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 Table 67: European Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 68: Nerve Repair and Regeneration Market in Europe in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 69: European Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 70: European Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 71: Nerve Repair and Regeneration Market in Europe: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 72: European Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 73: European Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 74: Nerve Repair and Regeneration Market in Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 75: European Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 FRANCE Table 76: Nerve Repair and Regeneration Market in France by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 77: French Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 78: French Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 79: Nerve Repair and Regeneration Quantitative Demand Analysis in France in US$ Thousand by Application: 2018-2025 Table 80: French Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 81: French Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 82: Nerve Repair and Regeneration Quantitative Demand Analysis in France in US$ Thousand by End-Use: 2018-2025 Table 83: French Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 84: French Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 GERMANY Table 85: Nerve Repair and Regeneration Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 86: German Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 87: German Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 88: Nerve Repair and Regeneration Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 89: German Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 90: Nerve Repair and Regeneration Market Share Distribution in Germany by Application: 2009 VS 2019 VS 2025 Table 91: Nerve Repair and Regeneration Market in Germany: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 92: German Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 93: Nerve Repair and Regeneration Market Share Distribution in Germany by End-Use: 2009 VS 2019 VS 2025 ITALY Table 94: Italian Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 95: Nerve Repair and Regeneration Historic Market Analysis in Italy in US$ Thousand by Product: 2009-2017 Table 96: Italian Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 97: Italian Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 98: Nerve Repair and Regeneration Market Review in Italy in US$ Thousand by Application: 2009-2017 Table 99: Italian Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 100: Italian Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 101: Nerve Repair and Regeneration Market Review in Italy in US$ Thousand by End-Use: 2009-2017 Table 102: Italian Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 UNITED KINGDOM Table 103: United Kingdom Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 104: Nerve Repair and Regeneration Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 105: United Kingdom Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 106: United Kingdom Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 107: United Kingdom Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 108: Nerve Repair and Regeneration Market Share Shift in the United Kingdom by Application: 2009 VS 2019 VS 2025 Table 109: United Kingdom Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2to 2025 Table 110: United Kingdom Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 111: Nerve Repair and Regeneration Market Share Shift in the United Kingdom by End-Use: 2009 VS 2019 VS 2025 SPAIN Table 112: Spanish Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 113: Spanish Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 114: Nerve Repair and Regeneration Market in Spain: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 115: Spanish Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 116: Nerve Repair and Regeneration Market in Spain: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 117: Spanish Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 118: Spanish Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 119: Nerve Repair and Regeneration Market in Spain: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 120: Spanish Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 RUSSIA Table 121: Russian Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 122: Nerve Repair and Regeneration Market in Russia by Product: A Historic Review in US$ Thousand for 2009-2017 Table 123: Russian Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 124: Russian Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 125: Nerve Repair and Regeneration Historic Demand Patterns in Russia by Application in US$ Thousand for 2009-2017 Table 126: Nerve Repair and Regeneration Market Share Breakdown in Russia by Application: 2009 VS 2019 VS 2025 Table 127: Russian Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 128: Nerve Repair and Regeneration Historic Demand Patterns in Russia by End-Use in US$ Thousand for 2009-2017 Table 129: Nerve Repair and Regeneration Market Share Breakdown in Russia by End-Use: 2009 VS 2019 VS 2025 REST OF EUROPE Table 130: Rest of Europe Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 131: Nerve Repair and Regeneration Market in Rest of Europe in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 132: Rest of Europe Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 133: Rest of Europe Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 134: Nerve Repair and Regeneration Market in Rest of Europe: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 135: Rest of Europe Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 136: Rest of Europe Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 137: Nerve Repair and Regeneration Market in Rest of Europe: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 138: Rest of Europe Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 ASIA-PACIFIC Table 139: Asia-Pacific Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 140: Nerve Repair and Regeneration Market in Asia-Pacific: Historic Market Analysis in US$ Thousand by Region/Country for the Period 2009-2017 Table 141: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 Table 142: Nerve Repair and Regeneration Market in Asia-Pacific by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 143: Asia-Pacific Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 144: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 145: Nerve Repair and Regeneration Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by Application: 2018-2025 Table 146: Asia-Pacific Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 147: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 148: Nerve Repair and Regeneration Quantitative Demand Analysis in Asia-Pacific in US$ Thousand by End-Use: 2018-2025 Table 149: Asia-Pacific Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 150: Asia-Pacific Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 AUSTRALIA Table 151: Nerve Repair and Regeneration Market in Australia: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 152: Australian Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 153: Australian Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 154: Nerve Repair and Regeneration Market in Australia: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 155: Australian Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 156: Nerve Repair and Regeneration Market Share Distribution in Australia by Application: 2009 VS 2019 VS 2025 Table 157: Nerve Repair and Regeneration Market in Australia: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 158: Australian Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 159: Nerve Repair and Regeneration Market Share Distribution in Australia by End-Use: 2009 VS 2019 VS 2025 INDIA Table 160: Indian Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 161: Indian Nerve Repair and Regeneration Historic Market Review by Product in US$ Thousand: 2009-2017 Table 162: Nerve Repair and Regeneration Market in India: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 163: Indian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 164: Nerve Repair and Regeneration Market in India: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 165: Indian Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 166: Indian Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 167: Nerve Repair and Regeneration Market in India: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 168: Indian Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 SOUTH KOREA Table 169: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 170: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 171: Nerve Repair and Regeneration Market Share Distribution in South Korea by Product: 2009 VS 2019 VS 2025 Table 172: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Application for the Period 2018-2025 Table 173: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Application: 2009-2017 Table 174: Nerve Repair and Regeneration Market Share Distribution in South Korea by Application: 2009 VS 2019 VS 2025 Table 175: Nerve Repair and Regeneration Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2018-2025 Table 176: South Korean Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by End-Use: 2009-2017 Table 177: Nerve Repair and Regeneration Market Share Distribution in South Korea by End-Use: 2009 VS 2019 VS 2025 REST OF ASIA-PACIFIC Table 178: Rest of Asia-Pacific Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 179: Nerve Repair and Regeneration Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 180: Rest of Asia-Pacific Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 181: Rest of Asia-Pacific Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 182: Rest of Asia-Pacific Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 183: Nerve Repair and Regeneration Market Share Shift in Rest of Asia-Pacific by Application: 2009 VS 2019 VS 2025 Table 184: Rest of Asia-Pacific Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 185: Rest of Asia-Pacific Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 186: Nerve Repair and Regeneration Market Share Shift in Rest of Asia-Pacific by End-Use: 2009 VS 2019 VS 2025 LATIN AMERICA Table 187: Latin American Nerve Repair and Regeneration Market Trends by Region/Country in US$ Thousand: 2018-2025 Table 188: Nerve Repair and Regeneration Market in Latin America in US$ Thousand by Region/Country: A Historic Perspective for the Period 2009-2017 Table 189: Latin American Nerve Repair and Regeneration Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 Table 190: Latin American Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 191: Nerve Repair and Regeneration Historic Market Analysis in Latin America in US$ Thousand by Product: 2009-2017 Table 192: Latin American Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 193: Latin American Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 194: Nerve Repair and Regeneration Market Review in Latin America in US$ Thousand by Application: 2009-2017 Table 195: Latin American Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 196: Latin American Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 197: Nerve Repair and Regeneration Market Review in Latin America in US$ Thousand by End-Use: 2009-2017 Table 198: Latin American Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 ARGENTINA Table 199: Argentinean Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 200: Nerve Repair and Regeneration Market in Argentina in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 201: Argentinean Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 202: Argentinean Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 203: Nerve Repair and Regeneration Market in Argentina: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 204: Argentinean Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 205: Argentinean Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 206: Nerve Repair and Regeneration Market in Argentina: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 207: Argentinean Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 BRAZIL Table 208: Nerve Repair and Regeneration Market in Brazil by Product: Estimates and Projections in US$ Thousand for the Period 2018-2025 Table 209: Brazilian Nerve Repair and Regeneration Historic Market Scenario in US$ Thousand by Product: 2009-2017 Table 210: Brazilian Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 211: Nerve Repair and Regeneration Quantitative Demand Analysis in Brazil in US$ Thousand by Application: 2018-2025 Table 212: Brazilian Nerve Repair and Regeneration Historic Market Review in US$ Thousand by Application: 2009-2017 Table 213: Brazilian Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by Application for 2009, 2019, and 2025 Table 214: Nerve Repair and Regeneration Quantitative Demand Analysis in Brazil in US$ Thousand by End-Use: 2018-2025 Table 215: Brazilian Nerve Repair and Regeneration Historic Market Review in US$ Thousand by End-Use: 2009-2017 Table 216: Brazilian Nerve Repair and Regeneration Market Share Analysis: A 17-Year Perspective by End-Use for 2009, 2019, and 2025 MEXICO Table 217: Nerve Repair and Regeneration Market in Mexico: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 218: Mexican Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 219: Mexican Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 220: Nerve Repair and Regeneration Market in Mexico: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 221: Mexican Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 222: Nerve Repair and Regeneration Market Share Distribution in Mexico by Application: 2009 VS 2019 VS 2025 Table 223: Nerve Repair and Regeneration Market in Mexico: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 224: Mexican Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 225: Nerve Repair and Regeneration Market Share Distribution in Mexico by End-Use: 2009 VS 2019 VS 2025 REST OF LATIN AMERICA Table 226: Rest of Latin America Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 227: Nerve Repair and Regeneration Market in Rest of Latin America by Product: A Historic Review in US$ Thousand for 2009-2017 Table 228: Rest of Latin America Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 229: Rest of Latin America Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 230: Nerve Repair and Regeneration Historic Demand Patterns in Rest of Latin America by Application in US$ Thousand for 2009-2017 Table 231: Nerve Repair and Regeneration Market Share Breakdown in Rest of Latin America by Application: 2009 VS 2019 VS 2025 Table 232: Rest of Latin America Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 233: Nerve Repair and Regeneration Historic Demand Patterns in Rest of Latin America by End-Use in US$ Thousand for 2009-2017 Table 234: Nerve Repair and Regeneration Market Share Breakdown in Rest of Latin America by End-Use: 2009 VS 2019 VS 2025 MIDDLE EAST Table 235: The Middle East Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 Table 236: Nerve Repair and Regeneration Market in the Middle East by Region/Country in US$ Thousand: 2009-2017 Table 237: The Middle East Nerve Repair and Regeneration Market Share Breakdown by Region/Country: 2009, 2019, and 2025 Table 238: The Middle East Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018 to 2025 Table 239: The Middle East Nerve Repair and Regeneration Historic Market by Product in US$ Thousand: 2009-2017 Table 240: Nerve Repair and Regeneration Market in the Middle East: Percentage Share Breakdown of Sales by Product for 2009, 2019, and 2025 Table 241: The Middle East Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by Application: 2018 to 2025 Table 242: Nerve Repair and Regeneration Market in the Middle East: Summarization of Historic Demand Patterns in US$ Thousand by Application for 2009-2017 Table 243: The Middle East Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 244: The Middle East Nerve Repair and Regeneration Market Quantitative Demand Analysis in US$ Thousand by End-Use: 2to 2025 Table 245: Nerve Repair and Regeneration Market in the Middle East: Summarization of Historic Demand Patterns in US$ Thousand by End-Use for 2009-2017 Table 246: The Middle East Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 IRAN Table 247: Iranian Market for Nerve Repair and Regeneration: Annual Sales Estimates and Projections in US$ Thousand by Product for the Period 2018-2025 Table 248: Nerve Repair and Regeneration Market in Iran: Historic Sales Analysis in US$ Thousand by Product for the Period 2009-2017 Table 249: Iranian Nerve Repair and Regeneration Market Share Analysis by Product: 2009 VS 2019 VS 2025 Table 250: Iranian Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 251: Iranian Nerve Repair and Regeneration Market in US$ Thousand by Application: 2009-2017 Table 252: Nerve Repair and Regeneration Market Share Shift in Iran by Application: 2009 VS 2019 VS 2025 Table 253: Iranian Demand Estimates and Forecasts for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 254: Iranian Nerve Repair and Regeneration Market in US$ Thousand by End-Use: 2009-2017 Table 255: Nerve Repair and Regeneration Market Share Shift in Iran by End-Use: 2009 VS 2019 VS 2025 ISRAEL Table 256: Israeli Nerve Repair and Regeneration Market Estimates and Forecasts in US$ Thousand by Product: 2018-2025 Table 257: Nerve Repair and Regeneration Market in Israel in US$ Thousand by Product: A Historic Review for the Period 2009-2017 Table 258: Israeli Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 259: Israeli Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by Application: 2018-2025 Table 260: Nerve Repair and Regeneration Market in Israel: Summarization of Historic Demand in US$ Thousand by Application for the Period 2009-2017 Table 261: Israeli Nerve Repair and Regeneration Market Share Analysis by Application: 2009 VS 2019 VS 2025 Table 262: Israeli Nerve Repair and Regeneration Addressable Market Opportunity in US$ Thousand by End-Use: 2018-2025 Table 263: Nerve Repair and Regeneration Market in Israel: Summarization of Historic Demand in US$ Thousand by End-Use for the Period 2009-2017 Table 264: Israeli Nerve Repair and Regeneration Market Share Analysis by End-Use: 2009 VS 2019 VS 2025 SAUDI ARABIA Table 265: Saudi Arabian Nerve Repair and Regeneration Market Growth Prospects in US$ Thousand by Product for the Period 2018-2025 Table 266: Nerve Repair and Regeneration Historic Market Analysis in Saudi Arabia in US$ Thousand by Product: 2009-2017 Table 267: Saudi Arabian Nerve Repair and Regeneration Market by Product: Percentage Breakdown of Sales for 2009, 2019, and 2025 Table 268: Saudi Arabian Demand for Nerve Repair and Regeneration in US$ Thousand by Application: 2018 to 2025 Table 269: Nerve Repair and Regeneration Market Review in Saudi Arabia in US$ Thousand by Application: 2009-2017 Table 270: Saudi Arabian Nerve Repair and Regeneration Market Share Breakdown by Application: 2009 VS 2019 VS 2025 Table 271: Saudi Arabian Demand for Nerve Repair and Regeneration in US$ Thousand by End-Use: 2018 to 2025 Table 272: Nerve Repair and Regeneration Market Review in Saudi Arabia in US$ Thousand by End-Use: 2009-2017 Table 273: Saudi Arabian Nerve Repair and Regeneration Market Share Breakdown by End-Use: 2009 VS 2019 VS 2025 UNITED ARAB EMIRATES Table 274: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 275: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 276: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by Product: 2009 VS 2VS 2025 Table 277: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Application for the Period 2018-2025 Table 278: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Application: 2009-2017 Table 279: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by Application: 2009 VS 2019 VS 2025 Table 280: Nerve Repair and Regeneration Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by End-Use for the Period 2018-2025 Table 281: United Arab Emirates Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by End-Use: 2009-2017 Table 282: Nerve Repair and Regeneration Market Share Distribution in United Arab Emirates by End-Use: 2009 VS 2VS 2025 REST OF MIDDLE EAST Table 283: Nerve Repair and Regeneration Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Thousand by Product for the Period 2018-2025 Table 284: Rest of Middle East Nerve Repair and Regeneration Historic Market Analysis in US$ Thousand by Product: 2009-2017 Table 285: Rest of Middle East Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 286: Nerve Repair and Regeneration Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Thousand by Application for the Period 2018-2025 Table 287: Rest of Middle East Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by Application: 2009-2017 Table 288: Nerve Repair and Regeneration Market Share Distribution in Rest of Middle East by Application: 2009 VS 2019 VS 2025 Table 289: Nerve Repair and Regeneration Market in Rest of Middle East: Annual Sales Estimates and Forecasts in US$ Thousand by End-Use for the Period 2018-2025 Table 290: Rest of Middle East Nerve Repair and Regeneration Market in Retrospect in US$ Thousand by End-Use: 2009-2017 Table 291: Nerve Repair and Regeneration Market Share Distribution in Rest of Middle East by End-Use: 2009 VS 2019 VS 2025 AFRICA Table 292: African Nerve Repair and Regeneration Market Estimates and Projections in US$ Thousand by Product: 2018 to 2025 Table 293: Nerve Repair and Regeneration Market in Africa by Product: A Historic Review in US$ Thousand for 2009-2017 Table 294: African Nerve Repair and Regeneration Market Share Breakdown by Product: 2009 VS 2019 VS 2025 Table 295: African Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by Application: 2018 to 2025 Table 296: Nerve Repair and Regeneration Historic Demand Patterns in Africa by Application in US$ Thousand for 2009-2017 Table 297: Nerve Repair and Regeneration Market Share Breakdown in Africa by Application: 2009 VS 2019 VS 2025 Table 298: African Nerve Repair and Regeneration Latent Demand Forecasts in US$ Thousand by End-Use: 2018 to 2025 Table 299: Nerve Repair and Regeneration Historic Demand Patterns in Africa by End-Use in US$ Thousand for 2009-2017 Table 300: Nerve Repair and Regeneration Market Share Breakdown in Africa by End-Use: 2009 VS 2019 VS 2025

IV. COMPETITION

Total Companies Profiled:

Read the full report: https://www.reportlinker.com/p05799212/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

Clare: clare@reportlinker.comUS: (339)-368-6001Intl: +1 339-368-6001

See the original post:
Global Nerve Repair and Regeneration Industry - Yahoo Finance

According to Masud Soleimani, who recently came home from illegal detainment in US, the research is being carried out with the support of the Health Ministry in two Tehran-based hospitals of Shariati and Masih Daneshvari.

The news came as some local media had earlier quoted Soleimani as saying that a drug for the disease has been developed.

In an interview with Mehr News Agency on Saturday night, Soleimani dismissed the reports as inaccurate, noting that this is not a drug but a method that is still being worked on.

The results of the first phase of its clinical trial will be announced soon by the Health Ministry, he added.

According to the latest announcement on Saturday, the number of confirmed cases of the COVID-19 has hit 35,408 in the country. 11,679 patients have recovered so far while the virus has claims 2,517 lives.

MAH/ 4888035

See the original post here:
Iranian scientists working on stem cell therapy to treat Covid-19 patients - Mehr News Agency - English Version